A 38-year-old patient immediately after being treated with CyberHeart’s technology

CyberHeart, a startup that is developing the world’s first non-invasive treatment for cardiac arrhythmias, has experienced tremendous clinical successes in the past few months.

“This is a game changer,” (for patients with irregular heart rhythm), said Dr. Melvin Scheinman, a professor of medicine at the University of California, San Francisco, and past president of the Heart Rhythm Society,

Monthly Spotlight: Stacy Enxing Seng

At the Fogarty Institute we depend on our board of seasoned professionals to help us continue to grow and adapt to the medtech market. That’s why we were delighted to add another elite name to our esteemed group, with Stacy Enxing Seng joining as our newest member. With nearly 30 years of experience in the medtech industry,

Clinical Evidence and Health Economics

Seminar Reviews the Importance of Clinical Evidence and Health Economics in Getting to Market

Many medical device entrepreneurs believe that the single most important milestone to achieve in gaining market adoption of their technology is regulatory approval. While certainly an essential step, it is often not sufficient.

START TYPING AND PRESS ENTER TO SEARCH